Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 22, 2008

BioMS Obtains $10M Milestone Fee from Eli Lilly

  • BioMS Medical received $10 million from Eli Lilly as a result of positive initial Phase II/III data from dirucotide (MBP8298) in secondary progressive multiple sclerosis. Interim analysis covered efficacy and safety data from the first 200 patients to complete the trial.

    BioMS obtained $87 million upfront in exchange for giving Eli Lilly worldwide, exclusive rights to MBP8298. The deal, which was inked in December 2007, calls for $400 million more in development and sales milestone fees.

    While the terms of the milestone payments are not being disclosed, a majority are linked to success in development, according to Amanda Spadel, investor relations manager for BioMS. In addition to the sales-based milestones, BioMS is also eligible for escalating royalties.

    Results from the ongoing Phase II/III MAESTRO-01 trial are expected in the second half of 2009. Lilly could decide at this point to take over the fiscal responsibility for further development.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »